keyword
MENU ▼
Read by QxMD icon Read
search

Veno-occlusive disease

keyword
https://www.readbyqxmd.com/read/29469225/successful-hematopoietic-stem-cell-transplantation-for-osteopetrosis-using-reduced-intensity-conditioning
#1
Bella Shadur, Irina Zaidman, Adeeb NaserEddin, Elana Lokshin, Fatma Hussein, Hodaya Cohen Oron, Batia Avni, Sigal Grisariu, Polina Stepensky
BACKGROUND: Infantile malignant osteopetrosis (IMO) is an autosomal recessive condition characterized by defective osteoclast activity, with hematopoietic bone marrow transplant being the only available cure. Over the past several years, new conditioning regimes and donor options have emerged, thus extending the possibility of cure to a greater number of patients and improving the outcomes of bone marrow transplant. Here we detail the outcomes of bone marrow transplant in a cohort of 31 patients treated with a combination of fludarabine, treosulphan, thiotepa, and antithymocyte globulin...
February 22, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29428338/extracorporeal-membrane-oxygenation-support-during-pregnancy-in-pulmonary-veno-occlusive-disease
#2
Carlos Ortiz-Bautista, María Jesús López-Gude, Jesús Grande García, José Luis Pérez-Vela, Virginia Pérez-González, Pilar Escribano-Subías
No abstract text is available yet for this article.
February 7, 2018: Revista Española de Cardiología
https://www.readbyqxmd.com/read/29425462/challenges-in-pulmonary-hypertension-controversies-in-treating-the-tip-of-the-iceberg
#3
Jason M Elinoff, Richa Agarwal, Christopher F Barnett, Raymond L Benza, Michael J Cuttica, Ahmed M Gharib, Michael P Gray, Paul M Hassoun, Anna R Hemnes, Marc Humbert, Todd M Kolb, Tim Lahm, Jane A Leopold, Stephen C Mathai, Vallerie V McLaughlin, Ioana R Preston, Erika B Rosenzweig, Oksana A Shlobin, Virginia D Steen, Roham T Zamanian, Michael A Solomon
The Critical Care Medicine Department of the National Institutes of Health Clinical Center and the Pulmonary Hypertension Association held a joint symposium to discuss "Challenges in Pulmonary Hypertension: Beating, Breathing, and Beyond." Communities of interest including patient advocates, clinicians, and academic investigators gathered together to raise awareness and highlight the challenges in diagnosing and treating pulmonary hypertension (PH). The current symposium focused on whether or not pulmonary arterial hypertension specific treatments are warranted as therapies for PH due to heart failure with preserved ejection fraction, interstitial lung disease, and pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis...
February 9, 2018: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/29413507/respiratory-effects-of-trichloroethylene
#4
REVIEW
Orianne Dumas, Thomas Despreaux, Frédéric Perros, Edmund Lau, Pascal Andujar, Marc Humbert, David Montani, Alexis Descatha
Trichloroethylene (TCE) is a chlorinated solvent that has been used widely around the world in the twentieth century for metal degreasing and dry cleaning. Although TCE displays general toxicity and is classified as a human carcinogen, the association between TCE exposure and respiratory disorders are conflicting. In this review we aimed to systematically evaluate the current evidence for the respiratory effects of TCE exposure and the implications for the practicing clinician. There is limited evidence of an increased risk of lung cancer associated with TCE exposure based on animal and human data...
January 2018: Respiratory Medicine
https://www.readbyqxmd.com/read/29396857/flai-fludarabine-cytarabine-idarubicin-plus-low-dose-gemtuzumab-ozogamicin-as-induction-therapy-in-cd33-positive-aml-final-results-and-long-term-outcome-of-a-phase-ii-multicenter-clinical-trial
#5
Anna Candoni, Cristina Papayannidis, Giovanni Martinelli, Erica Simeone, Michele Gottardi, Ilaria Iacobucci, Filippo Gherlinzoni, Giuseppe Visani, Michele Baccarani, Renato Fanin
The aim of this prospective clinical trial was to evaluate the efficacy and safety of a combination of Gemtuzumab-Ozogamicin (GO) and FLAI scheme (fludarabine, cytarabine, idarubicin) as a first-line therapy in CD33 positive acute myeloid leukemia (AML). We treated 130 consecutive patients, aged <65, with a median age of 52 years (range, 18-65). FLAI-GO induction regimen included fludarabine (30 mg/sqm) and cytarabine (2 g/sqm) on days 1-5; idarubicin (10 mg/sqm) on days 1, 3, and 5; and GO (3 mg/sqm) on day 6...
February 2, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29381191/efficacy-and-safety-analysis-by-age-cohort-of-inotuzumab-ozogamicin-in-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia-enrolled-in-ino-vate
#6
Elias J Jabbour, Daniel J DeAngelo, Matthias Stelljes, Wendy Stock, Michaela Liedtke, Nicola Gökbuget, Susan O'Brien, Tao Wang, M Luisa Paccagnella, Barbara Sleight, Erik Vandendries, Anjali S Advani, Hagop M Kantarjian
BACKGROUND: Inotuzumab ozogamicin (InO) has demonstrated efficacy and tolerability in patients aged 18 to 78 years with relapsed/refractory acute lymphoblastic leukemia (ALL) in the INO-VATE trial. This subset analysis compared the efficacy and safety of InO in younger and older patients. METHODS: Intent-to-treat analyses of morphologic responses and overall survival (OS) included 326 randomized patients, and safety assessments included 307 patients receiving 1 or more doses of the study treatment...
January 30, 2018: Cancer
https://www.readbyqxmd.com/read/29352703/inotuzumab-ozogamicin-in-combination-with-low-intensity-chemotherapy-for-older-patients-with-philadelphia-chromosome-negative-acute-lymphoblastic-leukaemia-a-single-arm-phase-2-study
#7
Hagop Kantarjian, Farhad Ravandi, Nicholas J Short, Xuelin Huang, Nitin Jain, Koji Sasaki, Naval Daver, Naveen Pemmaraju, Joseph D Khoury, Jeffrey Jorgensen, Yesid Alvarado, Marina Konopleva, Guillermo Garcia-Manero, Tapan Kadia, Musa Yilmaz, Gautam Bortakhur, Jan Burger, Steven Kornblau, William Wierda, Courtney DiNardo, Alessandra Ferrajoli, Jovitta Jacob, Rebecca Garris, Susan O'Brien, Elias Jabbour
BACKGROUND: Inotuzumab ozogamicin, an anti-CD22 monoclonal antibody bound to a toxin, calicheamicin, has shown single-agent activity in relapsed or refractory acute lymphoblastic leukaemia. We aimed to assess the activity and safety of inotuzumab ozogamicin in combination with low-intensity chemotherapy in older patients with acute lymphoblastic leukaemia. METHODS: We did a single-arm, phase 2 study at the MD Anderson Cancer Center (Houston, TX, USA). Eligible patients were aged 60 years or older and had newly diagnosed, Philadelphia chromosome-negative, acute lymphoblastic leukaemia, and an Eastern Cooperative Oncology Group performance status of 3 or lower...
January 15, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29350698/identification-and-management-sinusoidal-obstruction-syndrome-veno-occlusive-disease-eelated-to-hematopoietic-stem-cell-transplantation%C3%A2
#8
Mairéad Ní Chonghaile, Karen Wolownik
BACKGROUND: Sinusoidal obstruction syndrome (SOS), also called hepatic veno-occlusive disease (VOD), is a potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT) that affects about 1 in 7 patients undergoing this procedure. SOS/VOD is caused by the conditioning regimens administered prior to HSCT; in some cases, SOS/VOD results from chemotherapy alone. SOS/VOD usually develops within three weeks following HSCT; however, it can have later onset. 
...
February 1, 2018: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/29343015/-clinical-and-imaging-features-of-pulmonary-veno-occlusive-disease-and-pulmonary-capillary-hemangioma
#9
Q H Zhao, W H Wu, S G Gong, R Jiang, J He, C J Luo, H L Qiu, J L Li, J M Liu, L Wang
Objective: To improve the diagnosis and treatment of the pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangioma (PCH). Methods: The clinical features, radiological findings, laboratory testing and treatment in 8 cases of PVOD/PCH which was diagnosed from 2013 to 2017 were described. Results: PVOD/PCH was rare. The clinical symptoms were easily confused with IPAH, but the decrease of hypoxemia, clubbing, D(L)CO were more obvious, and the imaging features of HRCT were helpful for PVOD/PCH diagnosis...
January 12, 2018: Chinese Journal of Tuberculosis and Respiratory Diseases
https://www.readbyqxmd.com/read/29335623/sinusoidal-obstruction-syndrome-veno-occlusive-disease-after-high-dose-intravenous-busulfan-melphalan-conditioning-therapy-in-high-risk-ewing-sarcoma
#10
Massimo Eraldo Abate, Anna Paioli, Sivlia Cammelli, Marilena Cesari, Alessandra Longhi, Emanuela Palmerini, Stefano Ferrari, Elisa Carretta, Piero Picci, Fabio Piscaglia
This mono-institutional observational study was conducted to determine incidence, severity, risk factors, and outcome of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in high-risk Ewing sarcoma (ES) patients treated with intravenous busulfan and melphalan (BU-MEL) followed by autologous stem cell transplantation (ASCT). During the past 10 years, 75 consecutive ES patients resulted evaluable for the analysis. After diagnosis of SOS/VOD, defibrotide therapy was started as soon as the medication was available...
January 15, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29326798/late-onset-hepatic-veno-occlusive-disease-after-allografting-report-of-two-cases-with-atypical-clinical-features-successfully-treated-with-defibrotide
#11
Alessia Castellino, Stefano Guidi, Chiara Maria Dellacasa, Antonella Gozzini, Irene Donnini, Chiara Nozzoli, Sara Manetta, Semra Aydin, Luisa Giaccone, Moreno Festuccia, Lucia Brunello, Enrico Maffini, Benedetto Bruno, Ezio David, Alessandro Busca
Hepatic Veno-Occlusive Disease (VOD) is a potentially severe complication of hematopoietic stem cell transplantation (HSCT). Here we report two patients receiving an allogeneic HSCT who developed late onset VOD with atypical clinical features. The two patients presented with only few risk factors, namely, advanced acute leukemia, a myeloablative busulphan-containing regimen and received grafts from an unrelated donor. The first patient did not experience painful hepatomegaly and weight gain and both patients showed only a mild elevation in total serum bilirubin level...
2018: Mediterranean Journal of Hematology and Infectious Diseases
https://www.readbyqxmd.com/read/29325532/mesenteric-inflammatory-veno-occlusive-disease-occurring-during-the-course-of-ulcerative-colitis-a-case-report
#12
Yosuke Yamada, Ken Sugimoto, Yashiro Yoshizawa, Yoshifumi Arai, Yoshiro Otsuki, Tomio Arai, Yasuyuki Kobayashi, Yoshihiko Sato, Yoshisuke Hosoda
BACKGROUND: Mesenteric inflammatory veno-occlusive disease (MIVOD) is difficult to diagnose because of its rarity, nonspecific clinical findings, and frequent confusion with other diseases including inflammatory bowel disease. This report presents a very rare case of MIVOD that occurred during the course of ulcerative colitis (UC). CASE PRESENTATION: A 32-year-old man, who had been diagnosed with UC at the age of 29 and was in remission maintained by oral administration of 5-aminosalicylic acid (5-ASA), showed exacerbation of diarrhea and was admitted to the hospital...
January 11, 2018: BMC Gastroenterology
https://www.readbyqxmd.com/read/29301447/defibrotide-sodium-for-the-treatment-of-hepatic-veno-occlusive-disease-sinusoidal-obstruction-syndrome
#13
Paul G Richardson, Brandon M Triplett, Vincent T Ho, Nelson Chao, Fiona L Dignan, Michelle Maglio, Mohamad Mohty
Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is an unpredictable condition associated with endothelial-cell damage due to conditioning for hematopoietic stem-cell transplantation (HSCT) or chemotherapy without HSCT. Mortality in patients with VOD/SOS and multi-organ dysfunction (MOD) may be >80%. Areas covered: Defibrotide is the only approved drug for the treatment of severe hepatic VOD/SOS after HSCT in the European Union and hepatic VOD/SOS with renal or pulmonary dysfunction in the United States...
January 5, 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/29301090/evaluation-of-therapeutic-effect-of-rice-husk-silica-combined-with-platelets-derived-growth-factor-in-hepatic-veno-occlusive-disease
#14
Eithar K Al Adham, Amal I Hassan, M M Hazem, Ahmed Shebl
Veno- occlusive disease is an important pattern of hepatotoxicity associated with antineoplastic drugs. The study aimed to investigate the possible therapeutic impact of rice husk silica (RHS) nanoparticles combined with a platelet-derived growth factor (PDGF) on the Veno-occlusive disease in liver (VOD) elicited by dactinomycin (DAC) in rats. Forty-eight male Sprague-Dawely rats were classified into six groups, 8 rats each. The first group served as control, the second, animals were infused by intraperitoneal injection with DAC (0...
January 4, 2018: Biochemistry and Cell Biology, Biochimie et Biologie Cellulaire
https://www.readbyqxmd.com/read/29284886/monitored-anesthesia-care-for-the-acute-ischemic-stroke-patient-with-end-stage-pulmonary-disease
#15
Kevin C Lee, Brian C Lee, Steven E Miller
The majority of patients who suffer acute ischemic stroke (AIS) from large vessel occlusion are at a significant risk for disability or death. Because patients on veno-arterial extracorporeal membrane oxygenation (VA ECMO) are therapeutically anticoagulated, intravenous recombinant tissue plasminogen activator is contraindicated. For AIS management, these patients must undergo emergent intra-arterial therapy. Presented is a patient on VA ECMO who subsequently suffered a large vessel embolic stroke requiring emergent surgical intervention...
October 2017: Anesthesia, Essays and Researches
https://www.readbyqxmd.com/read/29284078/hepatobiliary-and-pancreatic-pregnancy-induced-hepatic-veno-occlusive-disease-requiring-liver-transplantation
#16
N Harimoto, K Yugawa, T Ikegami, M Ohira, Y Mano, T Motomura, T Toshima, S Itoh, N Harada, Y Soejima, T Yoshizumi, Y Maehara, Y Oda
No abstract text is available yet for this article.
January 2018: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29278102/hepatic-veno-occlusive-disease-during-isavuconazole-administration
#17
Alessio Mesini, Giuliana Cangemi, Elena Palmisani, Carlo Dufour, Elio Castagnola
No abstract text is available yet for this article.
December 26, 2017: Journal of Chemotherapy
https://www.readbyqxmd.com/read/29246894/global-pulmonary-vascular-remodeling-in-pulmonary-hypertension-associated-with-heart-failure-and-preserved-or-reduced-ejection-fraction
#18
Ahmed U Fayyaz, William D Edwards, Joseph J Maleszewski, Ewa A Konik, Hilary M DuBrock, Barry A Borlaug, Robert P Frantz, Sarah M Jenkins, Margaret M Redfield
Background -We hypothesized that pulmonary venous hypertension in heart failure (HF) leads to predominate remodeling of pulmonary veins and that the severity of venous remodeling is associated with the severity of pulmonary hypertension (PH) in HF. Methods -Patients with HF (n=108; 53 preserved and 55 reduced ejection fraction) with PH (HF-PH; pulmonary artery systolic pressure (PASP) ≥ 40 mmHg) were compared to normal Controls (n=12) and patients with primary pulmonary veno-occlusive disease (PVOD; n=17)...
December 15, 2017: Circulation
https://www.readbyqxmd.com/read/29229098/pulmonary-veno-occlusive-disease-an-important-consideration-in-patients-with-pulmonary-hypertension
#19
REVIEW
Ryan Balko, Hawa Edriss, Kenneth Nugent, Victor Test
Pulmonary veno-occlusive disease is a rare subcategory of pulmonary arterial hypertension (WHO Group 1). The disease is poorly understood and difficult to diagnose; it has no definitive cure to date. These patients present with nonspecific symptoms, including dyspnea, exercise intolerance, and weakness. Chest x-rays sometimes differ from idiopathic pulmonary arterial hypertension and may demonstrate alveolar infiltrates and pleural effusions. High resolution computed tomography scans reveal ground glass opacities, interlobular septal thickening, and lymphadenopathy...
November 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/29191686/ct-features-of-hepatic-veno-occlusive-disease-a-meta-analysis
#20
Song Yang, Jing Wu, Si Lei
RATIONALE AND OBJECTIVE: The computed tomography (CT) features of hepatic veno-occlusive disease (HVOD) could play a role in its diagnosis. We aimed to perform a meta-analysis of studies examining the CT features of HVOD. METHODS: Relevant studies published up to May 3, 2017 were searched in major electronic databases. The extracted data included the proportion of various CT features in patients with HVOD. The meta-analysis was conducted using R 3.3.3 with the "meta" package...
November 27, 2017: Academic Radiology
keyword
keyword
39013
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"